Conventional therapy ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
67	多発性嚢胞腎	2
222	一次性ネフローゼ症候群	1

67. 多発性嚢胞腎

臨床試験数 : 216 / 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01223755 (ClinicalTrials.gov)	September 2010	12/10/2010	Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency	EFFECTS OF SIROLIMUS ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND SEVERE RENAL INSUFFICIENCY	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Sirolimus;Drug: conventional therapy	Mario Negri Institute for Pharmacological Research	NULL	Terminated	18 Years	80 Years	Both	41	Phase 2/Phase 3	Italy
2	NCT00491517 (ClinicalTrials.gov)	March 2007	25/6/2007	Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	Sirolimus Treatment in Patients With ADPKD	Polycystic Kidney	Drug: Sirolimus;Drug: conventional therapy	Mario Negri Institute for Pharmacological Research	NULL	Completed	18 Years	80 Years	Both	22	Phase 2	Italy

222. 一次性ネフローゼ症候群

臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02966717 (ClinicalTrials.gov)	August 2016	30/10/2016	Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)	The Clinical Study of Rituximab Combined With Mesenchymal Stem Cells in the Treatment of Primary Nephrotic Syndrome (3-4 Stage of Chronic Kidney Disease)	Renal Insufficiency, Chronic;Nephrotic Syndrome	Drug: Rituximab;Drug: conventional therapy;Drug: Mesenchymal stem cells	Zhujiang Hospital	NULL	Active, not recruiting	18 Years	65 Years	Both	116	Phase 2	China